

BIOVERIS CORP  
Form 8-K  
January 13, 2005

---

**UNITED STATES SECURITIES  
AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K  
CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): January 13, 2005**

**BIOVERIS CORPORATION**

(Exact name of Registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-50583**  
(Commission  
File Number)

**80-0076765**  
(I.R.S. Employer  
Identification No.)

**16020 Industrial Drive**  
**Gaithersburg, MD 20877**  
(Address of Principal Executive  
Offices)

**46013**  
(Zip Code)

**(301) 869-9800**

(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01 Other Events.**

On January 13, 2005, BioVeris Corporation (the Company) announced that it completed an option agreement with Children's Hospital & Research Center at Oakland (CHRCO) for exclusive patent rights to a unique vaccine candidate for Neisseria meningitidis serogroup B, which causes meningitis, and a separate Sponsored Research Agreement under which the Company will sponsor up to \$800,000 of research at CHRCO

Edgar Filing: BIOVERIS CORP - Form 8-K

over a two-year period aimed at developing a vaccine candidate. See attached Press Release of the Company filed herewith as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

**(c) Exhibits**

99.1 Press Release dated January 13, 2005

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 13, 2005

BIOVERIS CORPORATION

By: /s/ George V. Migausky  
Name: George V. Migausky  
Title: Vice President of Finance and  
Chief Financial Officer

---

**EXHIBIT INDEX**

Exhibit 99.1 Press Release dated January 13, 2005